E-mail:gzliang@cqu.edu.cn    Tel: (86)2365102507

List of peptide properties
DFBP ID - DFBPHYCP0001(Hypocholesterolemic peptide)
DFBP ID DFBPHYCP0001
Peptide sequence IIAEK
Type Native peptide
Peptide/Function name Hypocholesterolemic peptide, Lactostatin
Function-activity relationship
Main bioactivity Hypocholesterolemic activity
Otheir bioactivity ACE-inhibitory activity [D1], Antioxidative activity [D2], DPP IV-inhibitory activity [D3], Multifunctional activity [D4]
Calculated physicochemical properties
Three-letter amino acid Ile-Ile-Ala-Glu-Lys
Single-letter amino acid IIAEK
Peptide length 5
Peptide mass
Experimental mass Theoretical mass
N.D 572.69 Da c
Net charge 0.00 c
Isoelectric point (pI) 6.92 c
IC50 N.D
pIC50 N.D
GRAVY 0.6800 c
Hydrophilic residue ratio 60% c
Peptide calculator
To calculate the physicochemical properties of bioactive peptide.
Peptide source & Food-borne protein(s) search
Classification Animal
Organism/Source Bovine milk protein
Precursor protein β-Lactoglobulin
Residue position f(71-75)
Precursor protein(s) search
Link-research
There are no literature reports on the discovery of this sequence in other food-source proteins.
Biological/Functional activity & target protein
Hypocholesterolemic activity
  1. The present study provides the first direct evidence that a new hypocholesterolemic peptide IIAEK derived from β-lactoglobuline can powerfully influence serum cholesterol levels and exhibit a greater hypocholesterolemic activity in comparison with that of medicine, β-sitosterol, in animal studies.

  2. By screening using Caco-2 cells and animal studies, the serum and liver cholesterol levels were significantly lower in rats fed β-lactoglobuline tryptic hydrolysate (LTH) than in those fed casein tryptic hydrolysate (CTH).

  3. The inhibition of micellar solubility of cholesterol which causes the suppression of cholesterol absorption by a direct interaction between cholesterol mixed micelles, and LTH in the jejunal epithelia is part of the mechanism underlying the hypocholesterolemic action of LTH.

Table 1. Effects of Oral Administration of Casein Tryptic Hydrolysate (CTH), β-Lactoglobulin Tryptic Hydrolysate (LTH), β-Sitosterol, or IIAEK on Body and Liver Weights, Food Intake, Serum HDL, and LDL + VLDL-cholesterol in Rats 1

Group
CTH
LTH
β-sitosterol
IIAEK
Body weight gain (g/4 days)
10.4 ± 0.4 a
10.5 ± 0.7 a
9.5 ± 0.8 a
8.7 ± 0.4 a
Liver weight (g/100 g body weight)
5.22 ± 0.07 b
5.37 ± 0.05 a, b
5.17 ± 0.10 b
5.54 ± 0.11 a
Food intake (day 3, g/day)
8.5 ± 0.2 a
8.7 ± 0.2 a
8.3 ± 0.3 a
8.4 ± 0.3 a
Serum (mg/dl)

Total cholesterol (a)
529.3 ± 14.4 a
441.3 ± 12.0 b
435.4 ± 12.8 b
328.7 ± 11.3 c
HDL cholesterol (b)
42.6 ± 1.6 b
50.5 ± 2.4 a
52.1 ± 1.7 a
47.5 ± 0.8 a, b
LDL + VLDL-cholesterol 2486.7 ± 26.7 a
390.8 ± 22.9 b
383.3 ± 24.2 b
281.2 ± 20.6 c
Atherogenic Index (b)/(a)
0.08 ± 0.01 c
0.11 ± 0.01 b
0.12 ± 0.01 b
0.15 ± 0.01 a
1 The data are means ± SEM (n = 7). Within a row, means with different superscript letters are significantly different (P < 0.05) by Duncan’s multiple range test.
2 Values were calculated as follows: LDL ± VLDL cholesterol = Total cholesterol — HDL cholesterol.
2001(3).png
FIG 1. Effects of fractionated peptides derived from β-lactoglobulin on cholesterol absorption in Caco-2 cells in vitro.
Specific target protein(s) N.D
Taste properties & Structure
Bitterness
Literature report N.D
Bitter prediction tools Bitter taste prediction
SMILES N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CCCCN)C(=O)O
Preparation method
Mode of preparation

Enzymatic hydrolysis

Enzyme(s)/starter culture

β-Lactoglobulin was hydrolyzed by porcine trypsin (Novo Industry, Bagsvaerd, Denmark) at pH 8.0 and 37℃ for 3 h.

Stability & Cytotoxicity
Peptide stability
Literature report: N.D
EHP-Tool: Enzymatic Hydrolysis Prediction Tool (EHP-Tool)
Peptide cytotoxicity
Literature report: N.D
Prediction: ToxinPred
Additional information
Additional information
  1. This finding of such a novel hypocholesterolemic peptide should play a crucial role in clarifying the mechanisms by which dietary protein induces differential effects on the serum cholesterol level as well as in developing a functional food or an anti-atherogenic drug.

  2. The researchers successfully developed a transgenic rice accumulating a much higher level of lactostatin by inserting 29 IIAEK sequences into the structurally flexible (nonconserved) regions of soybean seed storage protein, A1aB1b, and introducing it into LGC-1 (low glutelin content mutant 1) as host variety [2].

Database cross-references
DFBP
[D1] DFBPACEI0646
[D2] DFBPANOX0695
[D3] DFBPDPIV0212
[D4] DFBPMUFU0444
BIOPEP-UWM [D5] 9230, 9621
APD [D6] -
BioPepDB [D7] -
MBPDB [D8] -
Reference(s)
Primary literature Nagaoka S, Futamura Y, Miwa K, Awano T, Yamauchi K, Kanamaru Y, Tadashi K, Kuwata T. Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin. Biochem Biophys Res Commun. 2001 Feb 16;281(1):11-7.
PMID: 11178953
Other literature(s)

[1] Wakasa, Yuhya, Tamakoshi, Chiharu, Ohno, Tomoki, et al. The Hypocholesterolemic Activity of Transgenic Rice Seed Accumulating Lactostatin, a Bioactive Peptide Derived from Bovine Milk β-Lactoglobulin[J]. Journal of Agricultural & Food Chemistry, 2011, 59(8):3845-3850.
[2] Cabanos, Cerrone, Ekyo, Atsushi, Amari, Yoshiki, et al. High-level production of lactostatin, a hypocholesterolemic peptide, in transgenic rice using soybean A1aB1b as carrier[J]. Transgenic Research, 2013, 22(3):621-629.

PubDate 2001
Copyright © 2020. Record / license number: Chongqing ICP No. 2000214